Healthcare - Biotechnology - NASDAQ - US
$ 12.56
-7.58 %
$ 165 M
Market Cap
-15.9
P/E
CASH FLOW STATEMENT
-6.48 M
OPERATING CASH FLOW
0
INVESTING CASH FLOW
0
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Greenwich LifeSciences, Inc.
| Net Income | -8.89 M |
| Depreciation & Amortization | 3.61 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 2.38 M |
| Change in Working Capital | 31.5 K |
| Others | -3.97 K |
| Free Cash Flow | -6.48 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (8.9) | (7.8) | (4.6) | (1.9) | (3.4) | (1.7) | (1.6) |
| Depreciation & Amortization | 3.61 K | 3.61 K | 3.61 K | 3.61 K | 3.61 K | 3.61 K | 3.61 K |
| Deferred Income Tax | 0 | (1.8) | (1.2) | (0.8) | 0 | 0 | 0 |
| Stock Based Compensation | 2.4 | 1.7 | 0.7 | 0.7 | 0.2 | 0 | 0 |
| Other Operating Activities | 0 | 1.8 | 1.2 | 0.8 | 2 | 73.8 K | (0.1) |
| Change in Working Capital | 31.5 K | (0.1) | (0.4) | 28.4 K | 2.9 | 1.6 | 1.4 |
| Cash From Operations | (6.5) | (6.2) | (4.3) | (1.2) | (0.3) | (0.1) | (0.1) |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Items | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | 0 | (7.5) | 0 | 0 | 0 | 0 | 90 K |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 2.8 | (0.4) | 0.2 | 0.2 | (0.1) |
| Cash From Financing Activities | 0 | (7.5) | 2.8 | 29.8 | 0.2 | 0.2 | (0.1) |
| CHANGE IN CASH | |||||||
| Net Change In Cash | (6.5) | (13.7) | (1.5) | 28.7 | 78.3 K | 85 K | (0.3) |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (6.5) | (6.2) | (4.3) | (1.2) | (0.3) | (0.1) | (0.1) |